These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 30550256)

  • 21. Cognitive Enhancement: Unanswered Questions About Human Psychology and Social Behavior.
    Racine E; Sattler S; Boehlen W
    Sci Eng Ethics; 2021 Mar; 27(2):19. PubMed ID: 33759032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neuroethics of pharmaceutical cognitive enhancement: the first ten years: current problems and practical guiding principles].
    Metzinger TK
    Fortschr Neurol Psychiatr; 2012 Jan; 80(1):36-43. PubMed ID: 22234814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target.
    Barak S; Weiner I
    Pharmacol Biochem Behav; 2011 Aug; 99(2):164-89. PubMed ID: 21420999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people.
    Boot BP; Partridge B; Hall W
    Neurocase; 2012 Jun; 18(3):181-4. PubMed ID: 22007842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attitudes Toward Cognitive Enhancement: The Role of Metaphor and Context.
    Conrad EC; Humphries S; Chatterjee A
    AJOB Neurosci; 2019; 10(1):35-47. PubMed ID: 31070552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive Enhancement: Treating or Cheating?
    Whetstine LM
    Semin Pediatr Neurol; 2015 Sep; 22(3):172-6. PubMed ID: 26358427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ampakines and the threefold path to cognitive enhancement.
    Lynch G; Gall CM
    Trends Neurosci; 2006 Oct; 29(10):554-62. PubMed ID: 16890999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The potential of HDAC inhibitors as cognitive enhancers.
    Gräff J; Tsai LH
    Annu Rev Pharmacol Toxicol; 2013; 53():311-30. PubMed ID: 23294310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A neurological perspective on the enhancement debate: Lessons learned from Parkinson's disease.
    Kehagia AA
    J Psychopharmacol; 2016 Oct; 30(10):957-66. PubMed ID: 27604630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Neuro-enhancement. Brain doping].
    Förstl H
    Nervenarzt; 2009 Jul; 80(7):840-6. PubMed ID: 19565292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Neuroenhancement in healthy subject? A French case study].
    Micoulaud-Franchi JA; Vion-Dury J; Lancon C
    Therapie; 2012; 67(3):213-21. PubMed ID: 22874487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of transcranial electrical stimulation on cognition.
    Kuo MF; Nitsche MA
    Clin EEG Neurosci; 2012 Jul; 43(3):192-9. PubMed ID: 22956647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hippocampus: a target for cognition enhancers].
    Arushanian EB; Beĭer EV
    Eksp Klin Farmakol; 2007; 70(4):59-65. PubMed ID: 18078044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Use of Methylphenidate for Cognitive Enhancement in Young Healthy Adults: The Clinical and Ethical Debates.
    Koren G; Korn L
    J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):100-102. PubMed ID: 33666399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Nootropes (cognition enhancers) and neuroprotectors].
    Vornin TA; Seredenin SB
    Eksp Klin Farmakol; 2007; 70(4):44-58. PubMed ID: 18078043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute effects of modafinil on brain resting state networks in young healthy subjects.
    Esposito R; Cilli F; Pieramico V; Ferretti A; Macchia A; Tommasi M; Saggino A; Ciavardelli D; Manna A; Navarra R; Cieri F; Stuppia L; Tartaro A; Sensi SL
    PLoS One; 2013; 8(7):e69224. PubMed ID: 23935959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smart drugs and synthetic androgens for cognitive and physical enhancement: revolving doors of cosmetic neurology.
    Frati P; Kyriakou C; Del Rio A; Marinelli E; Vergallo GM; Zaami S; Busardò FP
    Curr Neuropharmacol; 2015 Jan; 13(1):5-11. PubMed ID: 26074739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experts urge smart thinking on cognitive enhancers.
    Morris K
    Lancet Neurol; 2008 Jun; 7(6):476-7. PubMed ID: 18485312
    [No Abstract]   [Full Text] [Related]  

  • 39. Ultra-low exposure to α-7 nicotinic acetylcholine receptor partial agonists elicits an improvement in cognition that corresponds with an increase in α-7 receptor expression in rodents: implications for low dose clinical efficacy.
    Werkheiser JL; Sydserff S; Hubbs SJ; Ding M; Eisman MS; Perry D; Williams AJ; Smith JS; Mrzljak L; Maier DL
    Neuroscience; 2011 Jul; 186():76-87. PubMed ID: 21550383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognition enhancers in age-related cognitive decline.
    Riedel WJ; Jolles J
    Drugs Aging; 1996 Apr; 8(4):245-74. PubMed ID: 8920174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.